The drug being tested in this study is called TAK-906. TAK-906 is being tested in healthy participants in order to evaluate safety and tolerability of single and multiple oral doses of TAK-906 in Japanese healthy male participants.~The study will enroll approximately 24 participants. Participants will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groups in Cohort 1 or Cohort 3. Study drug will be administered in a double-blind manner which will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need), orally, once daily on Day 1 as Single Dose Period and twice daily from Day 3 to 7 as Multiple Dose Period:~TAK-906 50 mg (Cohort 1)~TAK-906 100 mg (Cohort 2)~TAK-906 10 mg (Cohort 3)~Placebo (dummy inactive pill) - this is a tablet that looks like the study drug but has no active ingredient~Cohort 2 will be conducted after the completion of Cohort 1. This will be conducted in Japan.
The purpose of this study is to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of TAK-906 in Japanese healthy male participants.